Multinational Pharmaceutical Enterprises' Performance Changes In 2020: Revenue Growth Is Generally Weak, Innovative Medicine Is Still The Main Direction
Under the background of the new epidemic in 2020, multinational pharmaceutical companies are standing at the turning point.
In 2020, different from any previous year, under the influence of the epidemic situation superimposed on the medical policies of various countries, different market strategies will be selected to make the performance of each company present different features. At the same time, the fight against the new epidemic situation will also benefit the companies with relevant drugs, vaccines and testing.
From the perspective of revenue scale ranking, the biggest change comes from Pfizer, the "largest pharmaceutical company in the universe". Pfizer, which has been the champion for many years, withdrew from the "$50 billion club" due to the separation of Pfizer Upjohn, a non patent brand and generic drug business unit. Pfizer's ranking dropped sharply and nearly fell out of the top 10. However, only from the perspective of biopharmaceutical business performance, Pfizer still achieved growth; in addition, due to the new crown vaccine bnt162b2 cooperated with biontech, Pfizer remained in the spotlight in 2020, and obtained emergency use authorization (EUA) in the United States in December 2020, contributing $154 million in sales in the fourth quarter.
Pfizer's performance and changes in 2020, to a certain extent, reflect the new situation and new choices faced by major pharmaceutical enterprises: taking different actions to combat the epidemic of infectious diseases, and relying more on the pull of innovative drugs and the development of cutting-edge technology.
In addition, the financing environment for biopharmaceuticals has been very strong in recent years, and the epidemic in 2020 has accelerated this trend. With the focus on biopharmaceuticals, investors are scrambling to inject capital into the industry. Biopharmaceuticals have made significant progress in the development of therapeutic drugs for pandemic diseases.
Champion "change of ownership"
From the perspective of pharmaceutical performance in 2020, according to incomplete statistics of the 21st century economic report, there are five multinational pharmaceutical enterprises with pharmaceutical business revenue of more than 45 billion US dollars, but none of them has entered the "50 billion dollars club".
Roche's group revenue increased by 1% in 2020 to CHF 58.3 billion. Among them, Roche pharmaceutical business fell 2% to 44.5 billion Swiss francs. According to the exchange rate of February 23, Roche pharmaceutical business ranked first. In the pharmaceutical business, China's pharmaceutical business revenue was 3.143 billion Swiss francs, an increase of 8%. In 2021, Roche expects to maintain medium and low single digit growth.
Impacted by the successive listing of biological similar drugs in various markets, the revenue of Avastin, Herceptin and rituxan of Roche's traditional "troika" continued to decline, but the new drug business continued to drive growth (+ 32%, + 4.7 billion Swiss francs). In 2020, the sales volume reached 18.4 billion Swiss francs, accounting for more than 40%. It was mainly composed of tumor immunotherapy tecentriq, hemophilic drug hemlibra, multiple sclerosis Drugs ocrevus, breast cancer drugs perjeta, kadcyla pull. Commenting on the group's performance, Roche CEO Severin Schwan also stressed that "the demand for new drugs in these diseases is still high".
In addition, Roche's diagnostic business was the beneficiary sector under the covid-19 epidemic, reaching 13.791 billion Swiss francs (+ 14%), thanks to the sales of diagnostic kits.
In 2020, Novartis's net sales increased by 3% to US $48.7 billion, and its core operating profit increased by 13% to US $15.4 billion. Among them, the revenue in China increased by 16% to US $2.6 billion, leading the growth of emerging regional markets.
With a new generation of "drug king" candidate drugs, the performance of MSD in 2020 is still bright: the annual revenue is 47.994 billion US dollars, an increase of 2%. In 2020, keytruda's revenue will reach 14.38 billion US dollars, an increase of 30%, catching up with the "king of medicine" Humira.
The performance of MSD China led the global growth, with revenue of US $3.534 billion, a year-on-year increase of 13%. It is the highest growth region in the world and the third largest market of MSD except the United States and Europe.
Alberto and Bristol Myers Squibb (BMS) have become the "big winners" after the merger, with revenue of $40 billion.
Due to the completion of the acquisition of aierjian in May 2020, Aberdeen's revenue increased by 37.7% from US $33.266 billion in 2019 to US $45.804 billion in 2020, rising to the same volume as Roche, Novartis, MSD, Johnson & Johnson, and even surpass Pfizer.
After the acquisition, the company has enriched its product portfolio and reduced its dependence on xiumeile to a certain extent. Among them, the global revenue of immunization portfolio was 22.153 billion US dollars, an increase of 13.4%, and the global revenue of xiumeile was 19.832 billion US dollars; the revenue of blood tumor product portfolio was 6.651 billion US dollars (+ 21.7%); the income of aesthetic product portfolio was 2.59 billion US dollars.
BMS is another giant that has benefited greatly from M & A. as a result of the completion of the acquisition of Xinji, its revenue in 2020 will jump by 63% to US $42.518 billion, which is the same as that of Pfizer, while the revenue of BMS in 2019 is only 26.145 billion US dollars. Renalidomid contributed $12.106 billion (+ 12%) to become the sales champion of BMS; apixaban eliquis had revenue of $9.168 billion (+ 16%); compared with the "booming" of drug K, the revenue of opdivo decreased for the first time, 3% to $6.992 billion.
On February 16, the Berkshire Hathaway company of Warren Buffett announced the stock portfolio document of Q4 in 2020. Mr. Buffett cleared 3.7 million shares of Pfizer, increased the holding of moshadong by nearly 6.3 million, and increased the holdings of Alberto and BMS.
In addition, the annual revenue of radcivir, a highly epidemic related drug, was also announced in 2020. According to Gilead financial report, the annual revenue of 2020 is 24.689 billion US dollars, with a year-on-year increase of 10%. Among them, the revenue of radseway veklury was US $2.811 billion, driving the growth of Gilead in the whole year.
Information map.
Policy vs Market
The importance of China's market is self-evident. As the first country to recover from the epidemic, China's status as the "engine" is constantly improving. At the same time, from bulk purchase, national health insurance negotiation to new drug review and approval acceleration, the superimposed impact of policies more directly affects the strategy of multinational pharmaceutical enterprises for the Chinese market.
In an interview with the 21st century economic report, Novartis chief financial officer Harry Kirsch said in an interview with the 21st century economic report that "Novartis will grow well in the Chinese market in 2020, and its profit margin will be slightly lower than that in the mature market. This is mainly because we continue to invest in the future development of the Chinese market."
China has become one of Novartis's top three markets in the world, and Novartis is also one of the multinational pharmaceutical companies that benefited most from various pharmaceutical policies in 2020: a total of 6 new drugs and indications were approved in China in the whole year; simvastatin of sandex, a subsidiary of Novartis, was successfully selected by the state; a total of 8 products and new indications were successfully included in the 2020 national health insurance catalog through medical insurance negotiation. Since 1987, Novartis has approved more than 80 innovative drugs in China. Novartis expects to submit 50 new drug applications in China from 2020 to 2024, further accelerating the launch of new drugs.
"Novartis' performance in China is higher than the market average," Susan schaffert, global president of Novartis cancer, told the 21st century economic report. Since 2019, we have a number of drugs on the national health insurance list. "
Marie France Tschudin, the global president of Novartis, also told the 21st century economic report that "the Chinese government is more and more open to innovation, which also makes Novartis perform well in the Chinese market. Novartis cancer and Novartis pharmaceuticals are expected to have seven new products approved in China in 2021, and the opportunities we face are enormous. "
The Chinese market has become AstraZeneca's "main force" in the global market. In 2020, the global revenue of AstraZeneca is 26.617 billion US dollars, an increase of 10%. The revenue of Chinese market is as high as 5.375 billion US dollars, an increase of 10%. AstraZeneca is a "unique" among multinational pharmaceutical enterprises.
AstraZeneca said in its financial report that the rapid review of China's drug regulatory authorities has promoted drug development both domestically and globally. He also mentioned the impact of volume procurement and health care negotiations. In many markets, including the United States and China, pricing is still facing continued downward pressure. In key markets such as China, price and transparency measures remain a priority. In addition, AstraZeneca mentioned a very important trend after the outbreak, that is, digitization, "a lot of our business listings and conferences have turned to digital. For example, imfinzi is the first drug to be launched in a digital environment in China, attracting nearly 6000 medical staff to participate. "
The other foreign company that announced the revenue of China market for the first time was Lilly. In 2020, Lilly's revenue was 24.539 billion US dollars, with a year-on-year increase of 10%. Among them, China's revenue increased by 19% to 1.117 billion US dollars, and tyvyt (sindilimab), which cooperated with Cinda biology, contributed $308.7 million.
In 2021, in addition to balancing policy and market, multinational pharmaceutical enterprises continue to bet on innovative drugs, and add keywords of epidemic situation on the basis of previous years, which also leads to the investment direction in the new year: attention means capital, and covid-19 project of pharmaceutical and biotechnology companies will receive more financial support from investors in 2021.
- Related reading
Haizhu District Held CUHK Textile Business District Comprehensive Promotion Work Conference
|Excavator Sales Will Rise By 40% In 2020, And Demand Resilience Will Boost The High Prosperity Of The Industry
|"Variation" Of Property Market Policy: Pressure On "Big Cities" In Shanghai, Shenzhen And Hangzhou At The Beginning Of The New Year Has Gradually Become The Focus Of Regulation And Control
|- Fashion Bulletin | Yeezy Quantum Basketball Shoes New Flaora Color Appreciation
- Colorful circles | Kapok Road: 20 Elegant Names In Spring
- Recommended topics | Ministry Of Commerce: Vietnam'S Textile, Clothing, Leather And Footwear Exports Will Decrease Significantly In 2020
- Market trend | The Rise Of Grey Fabric Price In Peak Season Has Become A Common Phenomenon
- Market trend | Statistical Analysis Of Producer'S Ex Factory Price Index Of Cotton Textile And Printing And Dyeing Finishing Industry In January 2021
- Bullshit | Enjoy The New Three Party Ride Of Chah Chah X Lee
- Shoe Market | Recommendation: Yeezy'S New Shoes Challenge The Aesthetic Limit
- Fashion posters | Outdoor: Enjoy The New Co Branded Function Series Of Snow Peak X Tonedtrout
- Fashion shoes | Salomon X 11 By Boris Bidjan Saber
- Fashion brand | Vanquish X Kinjaz New Ride Series
- Hebei Air Pollution Appears Again: Shifting Peaks In The Game Of Cement Industry
- 2.5 Million Small And Micro Enterprises Will Benefit From The Reduction And Exemption Of Real Estate Tax And Urban Land Use Tax In Zhejiang Province For Half A Year
- Shenzhen Bureau Of Housing And Urban Rural Development Again: Make It Clear That Commercial Apartments And Dormitories Can Be Supplied With Gas To Ease The Tight Supply Of Residential Products
- Shenzhen Bureau Of Housing And Urban Rural Development Again: Make It Clear That Commercial Apartments And Dormitories Can Be Supplied With Gas To Ease The Tight Supply Of Residential Products
- Yeezy Quantum Basketball Shoes New Flaora Color Appreciation
- Kapok Road: 20 Elegant Names In Spring
- Ministry Of Commerce: Vietnam'S Textile, Clothing, Leather And Footwear Exports Will Decrease Significantly In 2020
- The Rise Of Grey Fabric Price In Peak Season Has Become A Common Phenomenon
- Statistical Analysis Of Producer'S Ex Factory Price Index Of Cotton Textile And Printing And Dyeing Finishing Industry In January 2021
- Enjoy The New Three Party Ride Of Chah Chah X Lee